Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
Provider: ValuEngine, Inc.
Provider: Finlabo SIM Spa

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG Strikes Collaboration With Seattle Genetics Inc Of Up To $520 Million-DJ

Tuesday, 25 Jun 2013 07:41am EDT 

Dow Jones reported that Seattle Genetics Inc has struck a new antibody-drug conjugate collaboration with Bayer AG under which Bayer AG will pay up to $520 million in connection with its use of Seattle Genetics' auristatin-based drug technology. Bayer AG will pay up to $20 million in upfront and option-exercise fees for world-wide rights to utilize the technology with antibodies to several oncology targets. Seattle Genetics Inc is also eligible to receive up to about $500 million in potential milestone payments, as well as royalties on world-wide net sales of any resulting products under the multi-target collaboration. Bayer AG is responsible for research, product development, manufacturing and commercialization of all products under the collaboration. 

Company Quote

0.35 +0.35%
11 Jul 2014